Chimerix (CMRX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CMRX Chimerix

Watchlist

4.600
-0.070-1.50%

Close Feb 26 16:00 ET

4.760
+0.160+3.48%

Pre 08:20 ET

413.88MMarket Cap-4.89P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Here Are Top-rated Defensive Stocks as Market Rally Sputters
Seeking AlphaFeb 23 12:16 ET
Institutional Investors Are Chimerix, Inc.'s (NASDAQ:CMRX) Biggest Bettors and Were Rewarded After Last Week's US$58m Market Cap Gain
Simply Wall StFeb 20 08:49 ET
Chimerix Delivers More Than 130% Gain In Less Than 3 Months
RTTNewsFeb 19 04:29 ET
Wedbush Maintains Chimerix(CMRX.US) With Buy Rating, Raises Target Price to $7
Moomoo NewsFeb 19 03:31 ET · Ratings
Sector Update: Health Care
MT NewswiresFeb 18 15:33 ET
Chimerix Analyst Ratings
BenzingaFeb 18 13:02 ET · Ratings

Comments

alson102446937

Feb 23 22:09

$Chimerix (CMRX.US)$ is one of the top 5 healthcare stocks with the highest momentum according to the Seeking Alpha Quant Rating system. It awards grades to stocks based on collective value, growth, profitability, earnings per share revisions, and price momentum metrics.~ Feb24

novice g

Feb 18 07:58

$Chimerix (CMRX.US)$

Share Your Profit/Loss

alson102446937

Feb 18 07:58

$Chimerix (CMRX.US)$ 120k volume overnight with price raised 15%+, Option ratio at Call 100%!!, FDA approval made a great Bullish momentum

Teddy123

Feb 18 06:22

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

$Chimerix (CMRX.US)$
Revolutionary Brain Cancer Drug Gets Fast-Track to FDA Approval: Chimerix's Hope for Untreatable Glioma

Jaguar8

Feb 18 06:09

NEWS

$Chimerix (CMRX.US)$
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
Chimerix (NASDAQ: CMRX) announced FDA acceptance of its New Drug Application (NDA) for dordaviprone, targeting recurrent H3 K27M-mutant diffuse glioma treatment. The application received Priority Review status with a PDUFA target action date of August 18, 2025.
The FDA has not planned an advisory committee meeting for th...

CMRX Chimerix

Trade Overview

Capital Trend

News

Comments

Trending Stocks